Differential miR-346 and miR-582-3p Expression in Association with Selected Maternal and Fetal Complications

Abstract

Several miRNAs are expressed in human gestational tissue, and some have been shown to be associated with placental dysfunction and complicated pregnancy outcomes. To investigate the roles of miR-346 and miR-582-3p in adverse obstetric events, we analyzed these 2 miRNAs in three samples (maternal blood, umbilical cord blood and placenta) obtained from pregnant women in four groups, including healthy control (n = 60), preeclampsia (n = 31), preterm delivery (n = 29) and small for gestational age (n = 19) patients. The expression levels of miR-346 and miR-582-3p in all included adverse obstetric outcome groups were significantly higher in the maternal plasma samples but lower in the placenta samples (all p value < 0.05). In addition, the miR-346 expression levels in fetal cord blood were also significantly lower in all of the included adverse obstetric outcome groups (all p < 0.05). Multivariate analysis of the three specimens after adjusting for maternal age and gestational age at delivery gave the same results. In conclusion, aberrant miR-346 and miR-582-3p expression level in pregnancy was associated with multiple maternal and fetal complications. Their differential expression in maternal blood, umbilical cord blood and placenta could be potential biomarkers or therapeutic targets for adverse obstetric outcomes

Screening for Gestational Diabetes Mellitus: The Potential of MicroRNAs

“…MiR-33b and miR-375 were overexpressed during macrosomia, while miR-454 was overexpressed in blood of both low birth weight and macrosomic compared to normal birth weight offspring [83]. Aberrant miR-346 and miR-582 expression in cord blood were shown to be associated with foetal complications [54]. Taken together, these studies provide evidence that GDM induces dysregulated miRNA expression in offspring, which may predispose them to metabolic disease in later life.…”

“…Subsequently, other studies have reported differential miRNA expression during preeclampsia and importantly provide experimental evidence to support the involvement of these miRNAs in disease pathophysiology [51,52]. Altered miRNA expression has also been observed in other pregnancy complications such as macrosomia [53], preterm delivery and small for gestational age [54].…”

“…Placental-derived miRNAs in maternal blood have potential as biomarkers for pregnancy monitoring [54,55]. It is suggested that miRNAs from placental tissue are exported into the maternal circulation via exosomes, and that these miRNAs reflect the physiological status of pregnancy and may thus have diagnostic potential [56].…”

“…Many of studies have reported that maternal circulating miRNAs are associated with placental weight [57], placental dysfunction [58,59] and pregnancy complications [54,[60][61][62][63]. MiR-517c was increased in pregnancies complicated with placental abruption [59], miR-515, miR-516a, miR-516b, miR-518b, miR-519d, miR-520a, miR-520h, miR-525, miR-526b and miR-1323 were increased during preeclampsia [63], miR-516, miR-517, miR-520a, miR-525 and miR-526a were upregulated during preeclampsia, gestational hypertension and foetal growth restriction [60], miR-517a was increased and miR-518b was decreased during placenta previa [58], and miR-346 and miR-582 were increased during preeclampsia, preterm delivery and small for gestational age patients compared to normal controls [54]. Importantly, Hromadnikova et al showed that upregulation of plasma miR-517, miR-518b and miR-520h during the first trimester was associated with the development of preeclampsia, and provided evidence to suggest that miR-517 could predict preeclampsia [61].…”

Elevated miR‐200a and miR‐141 inhibit endocrine gland‐derived vascular endothelial growth factor expression and ciliogenesis in preeclampsia

“…The whole blood samples (control, n = 55; preeclamptic group, n = 33) were prepared as per our previous publication (Tsai et al . ). Briefly, total RNA was extracted from plasma by using a commercial column‐based system (Direct‐zol RNA Miniprep kit, Zymo, Irvine, CA, USA).…”